ALNY — Alnylam Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $31.32bn
- $30.74bn
- $3.71bn
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Alnylam, Ionis fall as heart-drug data raise doubts over combination treatment
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
U.S. RESEARCH ROUNDUP-Apple, Amazon, Mastercard
Alnylam Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
U.S. STOCKS ON THE MOVE-Mastercard, Starbucks, Meta
Alnylam tumbles, eyes biggest drop in over 9 years after trimming product sales forecast
U.S. STOCKS ON THE MOVE-Avery Dennison, Huntington Ingalls, XPO
Alnylam slips after trimming 2026 product sales forecast
Alnylam Q2 revenue rises 67% on increased demand for AMVUTTRA
Brief: Alnylam Pharmaceuticals Q2 Adjusted EPS USD 1.84 Vs. IBES Estimate USD 1.55
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Sanofi sues Pfizer, Moderna over COVID shot technology
Ionis falls after AstraZeneca-partnered drug fails late-stage heart disease trial
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
U.S. STOCKS ON THE MOVE -Honeywell, Broadcom, Carlyle